Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 12:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Bronchiectasis
Interventions
GSK3862995B, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 85 Years
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
31
States / cities
Mobile, Alabama • Phoenix, Arizona • La Palma, California + 27 more
Conditions
Bronchiectasis
Interventions
Primary Care Educational event
Other
Lead sponsor
Hill-Rom
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Shelbyville, Tennessee
Conditions
Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis, Bronchiectasis, Pulmonary Vascular Disease
Interventions
Placebo, EZ-2053, EZ-2053 5mg/kg
Biological
Lead sponsor
Neovii Biotech
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 11 more
Recruiting No phase listed Observational Accepts healthy volunteers

Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease

NCT00807482
Conditions
Kartagener Syndrome
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Not yet recruiting Not applicable Interventional

Simeox 200 US Study

NCT07443124
Conditions
Bronchiectasis, Mucus; Plug
Interventions
Intermittent intrapulmonary deflation
Device
Lead sponsor
Inogen Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Non Cystic Fibrosis Bronchiectasis
Interventions
CMS, Placebo
Drug · Other
Lead sponsor
Zambon SpA
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
27
States / cities
Newport Beach, California • Palm Springs, California • Reseda, California + 22 more
Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
Galvokimig, Placebo
Biological
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Plantation, Florida • DuBois, Pennsylvania • McKinney, Texas
Conditions
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
Interventions
Clofazimine Inhalation Suspension, Placebo
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 85 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
54
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 47 more
Conditions
Bronchiectasis
Interventions
BI 1291583, Placebo matching BI 1291583
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Newport Beach, California • Sacramento, California • Gainesville, Florida + 8 more
Conditions
Idiopathic Bronchiectasis
Interventions
Nasal Nitric Oxide Measurement, Nasopharyngeal (Nasal) Samples
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Bronchiectasis
Interventions
280 mg Arikayce™, Matching Placebo for Cohort 1, 560 mg Arikayce™, Matching Placebo for Cohort 2
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Conditions
Bronchiectasis
Interventions
Ciprofloxacin (Cipro, BAYQ3939), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Little Rock, Arkansas • La Jolla, California • Denver, Colorado + 8 more
Completed No phase listed Observational Accepts healthy volunteers

A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults

NCT05685186
Conditions
Primary Ciliary Dyskinesia
Interventions
Spirometry, Multiple Breath Washout (MBW), Mucociliary Clearance (MCC), CT of the chest, MRI of the chest
Diagnostic Test
Lead sponsor
ReCode Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Primary Ciliary Dyskinesia
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
5 Years to 18 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
4
States / cities
Denver, Colorado • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Conditions
Bronchiectasis
Interventions
Ciprofloxacin DPI (BAYQ3939), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
39
States / cities
Jasper, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 34 more
Conditions
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
Interventions
AP-PA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
23
States / cities
Mobile, Alabama • Los Angeles, California • Farmington, Connecticut + 20 more
Conditions
Bronchiectasis, Bronchiectasis With Acute Exacerbation
Interventions
High Frequency Chest Wall Oscillation, Oscillating Positive Expiratory Pressure (OPEP)
Device
Lead sponsor
Hill-Rom
Industry
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
New York, New York • Nashville, Tennessee • Tyler, Texas
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections

NCT04884308
Conditions
Cystic Fibrosis, Bronchiectasis Adult, Non-Tuberculous Mycobacteria
Interventions
BCG TICE Vaccine
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Non-Cystic Fibrosis Bronchiectasis
Interventions
Brensocatib 10 mg, Brensocatib 25 mg, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 85 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Peoria, Arizona • Newport Beach, California + 30 more
Conditions
Cystic Fibrosis, Liver Disease or Abnormalities, Diabetes, Pancreatic Insufficiency (Exocrine and Endocrine)
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
4 Years to 120 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1988 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Cystic Fibrosis (CF), Non Cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Airway clearance therapy through acoustic oscillations
Device
Lead sponsor
Cognita Labs LLC
Industry
Eligibility
11 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Santa Ana, California
Recruiting No phase listed Observational Accepts healthy volunteers

Regional Phenotyping of CF and Non-CF Bronchiectasis

NCT04793867
Conditions
Cystic Fibrosis, Non-CF Bronchiectasis
Interventions
Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Nontuberculous Mycobacteria, Bronchiectasis
Interventions
Bronchoscopy
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2031
U.S. locations
1
States / cities
New York, New York
Conditions
Bronchiectasis
Interventions
AZLI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
24
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 21 more